Journal
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 58
Volume 58, Issue -, Pages 353-389Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-010716-104908
Keywords
mitochondrial dysfunction; UPRmt; mitophagy; proteostasis; neurodegeneration; metabolic syndrome
Categories
Funding
- NATIONAL INSTITUTE ON AGING [R01AG043930] Funding Source: NIH RePORTER
- CIHR Funding Source: Medline
- NIA NIH HHS [R01 AG043930] Funding Source: Medline
Ask authors/readers for more resources
Mitochondria are essential organelles for many aspects of cellular homeostasis, including energy harvesting through oxidative phosphorylation. Alterations of mitochondrial function not only impact on cellular metabolism but also critically influence whole-body metabolism, health, and life span. Diseases defined by mitochondrial dysfunction have expanded from rare monogenic disorders in a strict sense to now also include many common polygenic diseases, including metabolic, cardiovascular, neurodegenerative, and neuromuscular diseases. This has led to an intensive search for new therapeutic and preventive strategies aimed at invigorating mitochondrial function by exploiting key components of mitochondrial biogenesis, redox metabolism, dynamics, mitophagy, and the mitochondrial unfolded protein response. As such, new findings linking mitochondrial function to the progression or outcome of this ever-increasing list of diseases has stimulated the discovery and development of the first true mitochondrial drugs, which are now entering the clinic and are discussed in this review.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available